DOCSLIB.ORG

ERK5 Binding Partners

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ERK5 Binding Partners Supplementary Table 1: ERK5 binding partners id Protein IDs Protein namesGene namesRazor + uniqueSequence peptides coverageLFQ intensity [%]LFQ FL_m_01 intensityLFQ FL_m_02 intensityLFQ FL_m_03 intensityLFQ FL_p_01 intensityLFQ FL_p_02 intensityLFQ FL_p_03 intensityLFQ MU_p_01 intensityLFQ MU_p_02 intensitynormalized MU_p_03 normalizedLog2 IFL_m_01 normalizedLog2 IFL_m_02 normalizedLog2 IFL_m_03 normalizedLog2 IFL_p_01 normalizedLog2 IFL_p_02 normalizedLog2 IFL_p_03 normalizedLog2 IMU_p_01 normalizedLog2 IMU_p_02 medianLog2 IMU_p_03 - mediam FL median Mutst dev - st dev fl st dev mut cluster1 cluster2 cluster3 950 H7BXZ6 MitochondrialRHOT1 Rho GTPase 2 6.5 1.08E+08 26.77 26.77 + 405 B7WPL0 Synembryn-BRIC8B 2 6.1 9.55E+07 26.75 26.75 + 780 F6RFD5 Destrin DSTN 5 37.8 3.94E+07 25.49 25.49 + 360 B1AN48 Small proline-richSPRR3 protein 3 2 10.1 3.65E+07 25.24 25.24 + 1376 P02808 Statherin STATH 2 54.8 3.05E+07 25.12 25.12 + 196 A0A0A0MTI6Elongation ofELOVL5 very long chain fatty2 acids protein8.4 1.92E+07 1.52E+07 24.35 24.09 24.22 0.188066 + 2157 Q13163-4 Dual specificityMAP2K5 mitogen-activated6 protein18.7 kinase kinase 5 9.04E+06 2.09E+07 1.04E+07 8.78E+06 1.28E+07 1.06E+07 23.11 24.49 23.53 23.01 23.4 22.9 23.53 23.01 0.704014 0.263334 + 2702 Q96AB3-3 IsochorismataseISOC2 domain-containing2 protein28.1 2, mitochondrial 8.02E+06 23.1 23.1 + 64 A0A087WW54DEP domain-containingDEPDC7 protein 75 9.6 4.88E+06 7.56E+06 1.20E+07 3.13E+06 22.21 23.03 23.69 21.54 23.03 21.54 0.742829 + 1673 P30837 Aldehyde dehydrogenaseALDH1B1 X, mitochondrial5 13.7 4.26E+06 6.20E+06 6.14E+06 3.97E+06 22.04 22.78 22.81 21.87 22.78 21.87 0.438767 + 798 F8VW96 Cysteine andCSRP2 glycine-rich protein2 2 10.3 6.58E+06 22.68 22.68 + 1055 K7EMW4 Nicalin NCLN 3 8.6 6.52E+06 5.08E+06 22.83 22.53 22.68 0.210696 + 1343 O95983-2 Methyl-CpG-bindingMBD3 domain protein2 3 9.3 5.15E+06 22.57 22.57 3072 Q9NZN4 EH domain-containingEHD2 protein 24 10.5 4.97E+06 22.5 22.5 + 1888 P52435 DNA-directedPOLR2J RNA polymerase II2 subunit28.2 RPB11-a 4.85E+06 22.46 22.46 + 457 C9JF17 ApolipoproteinAPOD D 2 9.8 4.38E+06 22.26 22.26 + 1553 P18440 Arylamine N-acetyltransferaseNAT1 13 12.4 4.21E+06 3.09E+06 22.18 21.86 22.02 0.227825 + 2469 Q6ZVX7 F-box only proteinNCCRP1 50 3 18.9 8.06E+06 1.70E+06 2.29E+06 22.95 20.97 21.06 21.96 21.06 1.395383 + 1535 P16401 Histone H1.5HIST1H1B 2 11.9 3.27E+06 21.94 21.94 + 2487 Q7RTV0 PHD finger-likePHF5A domain-containing2 protein14.5 5A 3.25E+06 21.93 21.93 + 438 C9K0R9 Inosine-5-monophosphateIMPDH1 dehydrogenase2 11.1 2.63E+06 3.80E+06 21.56 22.15 21.85 0.416833 + 56 A0A087WVC1ATP-dependentDDX50 RNA helicase DDX502 6.6 3.07E+06 21.77 21.77 + 328 A6PVX1 Selenium-bindingSELENBP1 protein 1 2 6.4 2.72E+06 1.38E+06 21.69 20.26 21.69 20.26 + 1644 X6R6D0 SHC-transformingSHC1 protein 1 2 14.1 3.07E+06 2.84E+06 1.85E+06 21.57 21.68 21.14 21.57 0.285118 + 2654 Q92506 Estradiol 17-beta-dehydrogenaseHSD17B8 2 8 10.3 2.49E+06 21.56 21.56 + 252 A0A0D9SG07Band 4.1-likeEPB41L1 protein 1 3 6 2.41E+06 21.43 21.43 + 1449 P09104-2 Gamma-enolaseENO2 2 19.7 2.14E+06 21.36 21.36 3026 Q9NTX5-3 Ethylmalonyl-CoAECHDC1 decarboxylase2 8.4 1.98E+06 21.24 21.24 726 E9PNM1 Squalene synthaseFDFT1 2 5.1 2.40E+06 21.23 21.23 + 416 C9JEL3 Eukaryotic translationEIF4E2 initiation factor3 4E21.1 type 2 1.86E+06 21.16 21.16 + 2616 Q8TDL5 BPI fold-containingBPIFB1 family B member2 1 6.2 1.97E+06 21.12 21.12 + 2515 Q86WH2 Ras associationRASSF3 domain-containing2 protein8.4 3 1.78E+06 21.04 21.04 + 3169 Q9UNN5 FAS-associatedFAF1 factor 1 3 5.4 1.63E+06 20.89 20.89 + 2210 Q15424-2 Scaffold attachmentSAFB factor B1 3 8 1.48E+06 1.59E+06 1.82E+06 20.47 20.83 21.11 20.83 0.31803 + 2773 Q96QD9-2 UAP56-interactingFYTTD1 factor 2 8.2 1.48E+06 20.78 20.78 + 776 F5H702 39S ribosomalMRPL48 protein L48, mitochondrial2 21.2 1.45E+06 20.76 20.76 + 2931 Q9H2W6 39S ribosomalMRPL46 protein L46, mitochondrial2 7.5 1.17E+06 20.55 20.55 + 2658 Q92541 RNA polymerase-associatedRTF1 protein4 RTF1 6.1homolog 1.15E+06 20.53 20.53 + 2630 S5FZ81 PHD finger proteinPHF10 10 2 5.3 1.27E+06 20.52 20.52 + 902 H0YJV2 Serine palmitoyltransferaseSPTLC2 2 2 7.9 1.10E+06 20.48 20.48 + 648 E7EQY4 Metastasis-associatedMTA3 protein MTA32 13.6 1.06E+06 20.46 20.46 + 2041 P82932 28S ribosomalMRPS6 protein S6, mitochondrial2 12.8 9.82E+05 20.39 20.39 + 646 E9PES6 High mobilityHMGB3 group protein B3 2 17 8.95E+05 20.27 20.27 + 3121 Q9UH62 Armadillo repeat-containingARMCX3 X-linked2 protein6.3 3 1.01E+06 20.24 20.24 + 2291 Q15599-2 Na(+)/H(+) exchangeSLC9A3R2 regulatory 2cofactor NHE-RF28 6.62E+05 20.03 20.03 + 379 B4DLC8 Signal transducerSTAT2 and activator of3 transcription9.6 2 9.80E+05 8.66E+05 6.13E+05 19.98 20.01 19.95 19.98 0.030185 1063 K7EQQ8 tRNA (guanine(26)-N(2))-dimethyltransferaseTRMT1 2 6.1 5.59E+05 19.8 19.8 2872 Q9BWS9-3 Chitinase domain-containingCHID1 protein2 1 6.4 6.89E+05 19.74 19.74 + 663 E7EVU5 Nuclear receptorNCOR1 corepressor 1 2 5.2 4.66E+05 19.72 19.72 + 934 H3BPH4 PhosphomannomutasePMM2 2 15.5 4.53E+05 19.59 19.59 624 E5RIL9 Probable tRNAOSGEPL1 N6-adenosine threonylcarbamoyltransferase,2 10.8 mitochondrial 2.87E+05 19.33 19.33 + 2831 Q9BRP8-2 Partner of Y14WIBG and mago 2 14.3 5.02E+05 19.33 19.33 1561 P19474 E3 ubiquitin-proteinTRIM21 ligase TRIM2126 46.7 1.55E+08 7.67E+07 7.44E+08 4.85E+09 5.96E+09 4.09E+09 5.53E+09 1.17E+09 8.10E+09 27.26 26.45 29.97 32.17 32.59 32.26 32.02 29.97 32.02 27.26 32.26 32.02 1.846841 0.224012 1.182819 + 1233 O60701 UDP-glucoseUGDH 6-dehydrogenase15 35.8 1.96E+06 2.45E+06 6.14E+06 2.24E+07 7.98E+07 9.19E+07 2.02E+07 1.66E+06 3.42E+06 20.83 21.49 22.85 24.49 26.43 26.7 24.28 20.43 21.09 21.49 26.43 21.09 1.031141 1.206704 2.057839 + 207 A0A0B4J231ImmunoglobulinIGLL5 lambda-like polypeptide2 10.7 5 8.99E+07 2.81E+09 4.98E+09 1.25E+08 6.58E+09 26.77 31.41 32.25 27.26 32.43 26.77 31.41 32.43 2.669901 1972 P62191 26S proteasePSMC1 regulatory subunit10 4 29.5 2.46E+06 3.43E+06 4.24E+06 7.05E+06 8.77E+07 9.56E+07 5.80E+06 21.2 21.97 22.33 22.78 26.61 26.77 22.44 21.97 26.61 22.44 0.581541 2.255997 + 2066 Q01518-2 Adenylyl cyclase-associatedCAP1 protein14 1 34.6 1.15E+07 9.67E+06 3.36E+07 1.47E+08 1.75E+08 1.00E+08 2.07E+08 1.35E+07 4.04E+07 23.44 23.38 25.18 27.32 27.54 26.85 27.69 23.46 24.82 23.44 27.32 24.82 1.023728 0.350751 2.155749 + 2158 Q13164 Mitogen-activatedMAPK7 protein kinase47 7 44 1.55E+09 1.21E+09 1.18E+09 3.37E+10 3.47E+10 2.56E+10 1.10E+10 2.17E+10 4.92E+10 31.05 30.96 30.98 34.49 34.61 35.14 33.57 34.26 34.25 30.98 34.61 34.25 0.046764 0.347154 0.397241 + 1615 P25705 ATP synthaseATP5A1 subunit alpha, mitochondrial24 52.8 4.17E+07 2.51E+07 4.43E+07 8.79E+07 4.68E+08 4.12E+08 8.31E+07 3.89E+07 7.26E+07 25.3 24.74 25.64 26.55 28.96 28.91 26.29 25.03 25.54 25.3 28.91 25.54 0.456841 1.377217 0.63815 + 1784 P43490 NicotinamideNAMPT phosphoribosyltransferase13 28.9 7.52E+06 3.77E+06 1.02E+07 2.62E+07 6.06E+07 6.18E+07 4.61E+07 1.79E+07 2.87E+07 22.77 22.14 23.55 24.71 26.06 26.1 25.41 23.88 24.3 22.77 26.06 24.3 0.707558 0.794333 0.788737 + 871 H0Y4R1 Inosine-5-monophosphateIMPDH2 dehydrogenase14 35.5 2 3.44E+06 9.31E+06 9.31E+06 2.03E+07 8.64E+07 1.01E+08 8.06E+06 21.68 23.32 23.42 24.32 26.58 26.86 22.88 23.32 26.58 22.88 0.978356 1.390409 + 914 H0YMV8 40S ribosomalRPS27L protein S27 3 32 7.96E+06 5.72E+07 23.21 25.97 23.21 25.97 1350 P00390-2 GlutathioneGSR reductase, mitochondrial5 14.8 3.03E+06 2.45E+06 9.38E+06 2.40E+07 1.77E+07 9.43E+06 21.78 21.53 23.17 24.63 24.33 23.12 21.65 24.33 23.12 0.175361 0.772106 + 1759 P41091 Eukaryotic translationEIF2S3 initiation15 factor 2 subunit47 8.15E+06 3 3.08E+06 2.75E+07 3.28E+07 4.44E+07 1.28E+08 2.64E+07 2.32E+06 1.31E+07 22.92 21.81 24.91 25.08 25.55 27.34 24.65 20.98 23.24 22.92 25.55 23.24 1.571962 1.192313 1.854249 + 1635 P27797 CalreticulinCALR 11 43.6 7.44E+06 3.16E+06 5.31E+07 2.78E+07 3.53E+07 8.04E+07 2.56E+07 22.76 21.85 25.94 24.78 25.24 26.53 24.62 22.76 25.24 24.62 2.14908 0.910104 + 3135 Q9UI12-2 V-type protonATP6V1H ATPase subunit H9 26.5 3.79E+06 4.23E+06 1.40E+07 1.91E+07 3.42E+07 2.33E+07 2.61E+07 8.46E+06 1.49E+07 21.83 22.28 23.96 24.23 25.18 24.69 24.65 22.79 23.44 22.28 24.69 23.44 1.123569 0.4735 0.940296 + 2853 Q9BUA3 UncharacterizedC11orf84 protein C11orf8415 58.8 8.55E+07 5.17E+07 8.44E+07 2.65E+08 3.67E+08 2.98E+08 4.08E+08 1.81E+08 4.26E+08 26.36 25.82 26.66 28.07 28.56 28.61 28.54 27.24 27.93 26.36 28.56 27.93 0.425094 0.295866 0.654708 + 2325 Q16763 Ubiquitin-conjugatingUBE2S enzyme E22 S 8.6 9.47E+05 4.27E+06 20.2 22.3 20.2 22.3 681 E9PDI2 Adenylyl cyclase-associatedCAP2 protein16 42.4 6.87E+07 2.67E+07 6.19E+07 2.81E+08 2.52E+08 1.72E+08 3.38E+08 1.16E+08 4.48E+08 25.98 24.84 26.16 28.15 28.06 27.77 28.23 26.57 28.08 25.98 28.06 28.08 0.716431 0.197281 0.921684 + 2381 Q5SWX8 Protein odr-4ODR4 homolog 21 41.6 1.07E+08 9.09E+07 1.18E+08 4.41E+08 4.19E+08 3.39E+08 3.96E+08 3.06E+08 4.14E+08 26.77 26.69 27.12 28.73 28.79 28.69 28.46 27.85 27.85 26.77 28.73 27.85 0.230928 0.054329 0.35191 + 1501 P12273 Prolactin-induciblePIP protein 3 28.1 5.90E+06 3.60E+06 1.31E+07 2.06E+07 2.34E+07 1.65E+07 8.89E+06 4.38E+07 22.41 22.05 23.9 24.35 24.6 24.2 23.03 25.16 22.41 24.35 24.1 0.98035 0.201854 1.509257 + 2477 Q71U36-2 Tubulin alpha-1ATUBA1A chain 3 71.4 2.13E+07 5.52E+07 3.88E+07 1.43E+08 1.18E+08 1.86E+08 8.65E+07 24.49 26 25.32 27.24 27.15 27.5 26.17 25.25 27.15 26.84 1.069677 1.085712 0.941436 + 3130 Q9UHL4 Dipeptidyl peptidaseDPP7 2 10 24.2 3.93E+07 3.72E+07 5.00E+07 8.18E+07 1.46E+08 1.22E+08 1.37E+08 2.82E+07 4.57E+07 25.22 25.34 25.88 26.41 27.31 27.22 27.07 24.57 24.97 25.34 27.22
Load more

Recommended publications
  • Exosomes Confer Chemoresistance to Pancreatic Cancer Cells By
    FULL PAPER British Journal of Cancer (2017) 116, 609–619 | doi: 10.1038/bjc.2017.18 Keywords: chemoresistance; exosomes; pancreatic cancer; ROS; microRNA Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK Girijesh Kumar Patel1, Mohammad Aslam Khan1, Arun Bhardwaj1, Sanjeev K Srivastava1, Haseeb Zubair1, Mary C Patton1, Seema Singh1,2, Moh’d Khushman3 and Ajay P Singh*,1,2 1Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA; 2Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, USA and 3Department of Interdisciplinary Clinical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA Background: Chemoresistance is a significant clinical problem in pancreatic cancer (PC) and underlying molecular mechanisms still remain to be completely understood. Here we report a novel exosome-mediated mechanism of drug-induced acquired chemoresistance in PC cells. Methods: Differential ultracentrifugation was performed to isolate extracellular vesicles (EVs) based on their size from vehicle- or gemcitabine-treated PC cells. Extracellular vesicles size and subtypes were determined by dynamic light scattering and marker profiling, respectively. Gene expression was examined by qRT-PCR and/or immunoblot analyses, and direct targeting of DCK by miR-155 was confirmed by dual-luciferase 30-UTR reporter assay. Flow cytometry was performed to examine the apoptosis indices and reactive oxygen species (ROS) levels in PC cells using specific dyes. Cell viability was determined using the WST-1 assay. Results: Conditioned media (CM) from gemcitabine-treated PC cells (Gem-CM) provided significant chemoprotection to subsequent gemcitabine toxicity and most of the chemoresistance conferred by Gem-CM resulted from its EVs fraction.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Genes with 5' Terminal Oligopyrimidine Tracts Preferentially Escape Global Suppression of Translation by the SARS-Cov-2 NSP1 Protein
    Downloaded from rnajournal.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Genes with 5′ terminal oligopyrimidine tracts preferentially escape global suppression of translation by the SARS-CoV-2 Nsp1 protein Shilpa Raoa, Ian Hoskinsa, Tori Tonna, P. Daniela Garciaa, Hakan Ozadama, Elif Sarinay Cenika, Can Cenika,1 a Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA 1Corresponding author: [email protected] Key words: SARS-CoV-2, Nsp1, MeTAFlow, translation, ribosome profiling, RNA-Seq, 5′ TOP, Ribo-Seq, gene expression 1 Downloaded from rnajournal.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract Viruses rely on the host translation machinery to synthesize their own proteins. Consequently, they have evolved varied mechanisms to co-opt host translation for their survival. SARS-CoV-2 relies on a non-structural protein, Nsp1, for shutting down host translation. However, it is currently unknown how viral proteins and host factors critical for viral replication can escape a global shutdown of host translation. Here, using a novel FACS-based assay called MeTAFlow, we report a dose-dependent reduction in both nascent protein synthesis and mRNA abundance in cells expressing Nsp1. We perform RNA-Seq and matched ribosome profiling experiments to identify gene-specific changes both at the mRNA expression and translation level. We discover that a functionally-coherent subset of human genes are preferentially translated in the context of Nsp1 expression. These genes include the translation machinery components, RNA binding proteins, and others important for viral pathogenicity. Importantly, we uncovered a remarkable enrichment of 5′ terminal oligo-pyrimidine (TOP) tracts among preferentially translated genes.
    [Show full text]
  • EIF4E Antibody Cat
    EIF4E Antibody Cat. No.: 60-600 EIF4E Antibody Formalin-fixed and paraffin-embedded human breast carcinoma reacted with EIF4E antibody (N-term), which was peroxidase- conjugated to the secondary antibody, followed by DAB staining. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human Predicted species reactivity based on immunogen sequence: Zebrafish, Bovine, Mouse, HOMOLOGY: Rabbit, Rat, Xenopus This EIF4E antibody is generated from rabbits immunized with a KLH conjugated synthetic IMMUNOGEN: peptide between 32-61 amino acids from the N-terminal region of human EIF4E. TESTED APPLICATIONS: IHC-P, WB For WB starting dilution is: 1:1000 APPLICATIONS: For IHC-P starting dilution is: 1:50~100 September 27, 2021 1 https://www.prosci-inc.com/eif4e-antibody-60-600.html PREDICTED MOLECULAR 25 kDa WEIGHT: Properties This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by PURIFICATION: dialysis CLONALITY: Polyclonal ISOTYPE: Rabbit Ig CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: Supplied in PBS with 0.09% (W/V) sodium azide. CONCENTRATION: batch dependent Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies STORAGE CONDITIONS: care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: EIF4E Eukaryotic translation initiation factor 4E, eIF-4E, eIF4E, eIF-4F 25 kDa subunit, mRNA cap- ALTERNATE NAMES: binding protein, EIF4E, EIF4EL1, EIF4F ACCESSION NO.: P06730 PROTEIN GI NO.: 1352435 GENE ID: 1977 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions.
    [Show full text]
  • Early Growth Response 1 Regulates Hematopoietic Support and Proliferation in Human Primary Bone Marrow Stromal Cells
    Hematopoiesis SUPPLEMENTARY APPENDIX Early growth response 1 regulates hematopoietic support and proliferation in human primary bone marrow stromal cells Hongzhe Li, 1,2 Hooi-Ching Lim, 1,2 Dimitra Zacharaki, 1,2 Xiaojie Xian, 2,3 Keane J.G. Kenswil, 4 Sandro Bräunig, 1,2 Marc H.G.P. Raaijmakers, 4 Niels-Bjarne Woods, 2,3 Jenny Hansson, 1,2 and Stefan Scheding 1,2,5 1Division of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2Lund Stem Cell Center, Depart - ment of Laboratory Medicine, Lund University, Lund, Sweden; 3Division of Molecular Medicine and Gene Therapy, Department of Labora - tory Medicine, Lund University, Lund, Sweden; 4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands and 5Department of Hematology, Skåne University Hospital Lund, Skåne, Sweden ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.216648 Received: January 14, 2019. Accepted: July 19, 2019. Pre-published: August 1, 2019. Correspondence: STEFAN SCHEDING - [email protected] Li et al.: Supplemental data 1. Supplemental Materials and Methods BM-MNC isolation Bone marrow mononuclear cells (BM-MNC) from BM aspiration samples were isolated by density gradient centrifugation (LSM 1077 Lymphocyte, PAA, Pasching, Austria) either with or without prior incubation with RosetteSep Human Mesenchymal Stem Cell Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada) for lineage depletion (CD3, CD14, CD19, CD38, CD66b, glycophorin A). BM-MNCs from fetal long bones and adult hip bones were isolated as reported previously 1 by gently crushing bones (femora, tibiae, fibulae, humeri, radii and ulna) in PBS+0.5% FCS subsequent passing of the cell suspension through a 40-µm filter.
    [Show full text]
  • Mtorc1 Controls Mitochondrial Activity and Biogenesis Through 4E-BP-Dependent Translational Regulation
    Cell Metabolism Article mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation Masahiro Morita,1,2 Simon-Pierre Gravel,1,2 Vale´ rie Che´ nard,1,2 Kristina Sikstro¨ m,3 Liang Zheng,4 Tommy Alain,1,2 Valentina Gandin,5,7 Daina Avizonis,2 Meztli Arguello,1,2 Chadi Zakaria,1,2 Shannon McLaughlan,5,7 Yann Nouet,1,2 Arnim Pause,1,2 Michael Pollak,5,6,7 Eyal Gottlieb,4 Ola Larsson,3 Julie St-Pierre,1,2,* Ivan Topisirovic,5,7,* and Nahum Sonenberg1,2,* 1Department of Biochemistry 2Goodman Cancer Research Centre McGill University, Montreal, QC H3A 1A3, Canada 3Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 171 76, Sweden 4Cancer Research UK, The Beatson Institute for Cancer Research, Switchback Road, Glasgow G61 1BD, Scotland, UK 5Lady Davis Institute for Medical Research 6Cancer Prevention Center, Sir Mortimer B. Davis-Jewish General Hospital McGill University, Montreal, QC H3T 1E2, Canada 7Department of Oncology, McGill University, Montreal, QC H2W 1S6, Canada *Correspondence: [email protected] (J.S.-P.), [email protected] (I.T.), [email protected] (N.S.) http://dx.doi.org/10.1016/j.cmet.2013.10.001 SUMMARY ATP under physiological conditions in mammals and play a crit- ical role in overall energy balance (Vander Heiden et al., 2009). mRNA translation is thought to be the most energy- The mechanistic/mammalian target of rapamycin (mTOR) is a consuming process in the cell. Translation and serine/threonine kinase that has been implicated in a variety of energy metabolism are dysregulated in a variety of physiological processes and pathological states (Zoncu et al., diseases including cancer, diabetes, and heart 2011).
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION eIF4E (human recombinant) Item No. 15137 Overview and Properties Synonyms: eIF-4F 25 kDa subunit, Eukaryotic Translation Initiation Factor 4E, mRNA Cap-binding Protein Source: Recombinant protein expressed in E. coli Amino Acids: 2-217 (full length) Uniprot No.: P06730 Molecular Weight: 25.2 kDa Storage: -80°C (as supplied) Stability: ≥1 year Purity: batch specific (≥55% estimated by SDS-PAGE) Supplied in: 20 mM HEPES, pH 7.5, containing 100 mM potassium chloride, 2 mM DTT, and 10% glycerol Protein Concentration: batch specific mg/ml Image 1 2 3 4 250 kDa · · · · · · · 150 kDa · · · · · · · 100 kDa · · · · · · · 75 kDa · · · · · · · 50 kDa · · · · · · · 37 kDa · · · · · · · 25 kDa · · · · · · · 20 kDa · · · · · · · 15 kDa · · · · · · · Lane 1: MW Markers Lane 2: eIF4E (human recombinant) (4 µg) Lane 3: eIF4E (human recombinant) (2 µg) Lane 4: eIF4E (human recombinant) (1 µg) Representaõve gel image shown; actual purity may vary between each batch. WARNING CAYMAN CHEMICAL THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE. 1180 EAST ELLSWORTH RD SAFETY DATA ANN ARBOR, MI 48108 · USA This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution. PHONE: [800] 364-9897 WARRANTY AND LIMITATION OF REMEDY [734] 971-3335 Buyer agrees to purchase the material subject to Cayman’s Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.
    [Show full text]
  • Knockdown of RRM1 with Adenoviral Shrna Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
    International Journal of Molecular Sciences Article Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells Xia Zhang 1, Rikiya Taoka 1,*, Dage Liu 2, Yuki Matsuoka 1, Yoichiro Tohi 1 , Yoshiyuki Kakehi 1 and Mikio Sugimoto 1 1 Department of Urology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan; [email protected] (X.Z.); [email protected] (Y.M.); [email protected] (Y.T.); [email protected] (Y.K.); [email protected] (M.S.) 2 Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-87-891-2202 Abstract: RRM1—an important DNA replication/repair enzyme—is the primary molecular gem- citabine (GEM) target. High RRM1-expression associates with gemcitabine-resistance in various cancers and RRM1 inhibition may provide novel cancer treatment approaches. Our study eluci- dates how RRM1 inhibition affects cancer cell proliferation and influences gemcitabine-resistant bladder cancer cells. Of nine bladder cancer cell lines investigated, two RRM1 highly expressed cells, 253J and RT112, were selected for further experimentation. An RRM1-targeting shRNA was Citation: Zhang, X.; Taoka, R.; Liu, cloned into adenoviral vector, Ad-shRRM1. Gene and protein expression were investigated using D.; Matsuoka, Y.; Tohi, Y.; Kakehi, Y.; real-time PCR and western blotting.
    [Show full text]
  • EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis Through ATF4 and C-MYC
    Published OnlineFirst October 10, 2018; DOI: 10.1158/2159-8290.CD-18-0606 RESEARCH ARTICLE EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC Gnana P. Krishnamoorthy 1 , Natalie R. Davidson 2 , Steven D. Leach 1 , Zhen Zhao 3 , Scott W. Lowe 3 , Gina Lee 4 , Iňigo Landa 1 , James Nagarajah 1 , Mahesh Saqcena 1 , Kamini Singh 3 , Hans-Guido Wendel3 , Snjezana Dogan 5 , Prasanna P. Tamarapu 1 , John Blenis 4 , Ronald A. Ghossein 5 , Jeffrey A. Knauf 1 , 6 , Gunnar Rätsch 2 , and James A. Fagin 1 , 6 ABSTRACT Translation initiation is orchestrated by the cap binding and 43S preinitiation com- plexes (PIC). Eukaryotic initiation factor 1A (EIF1A) is essential for recruitment of the ternary complex and for assembling the 43S PIC. Recurrent EIF1AX mutations in papillary thyroid cancers are mutually exclusive with other drivers, including RAS . EIF1AX mutations are enriched in advanced thyroid cancers, where they display a striking co-occurrence with RAS , which cooperates to induce tumorigenesis in mice and isogenic cell lines. The C-terminal EIF1AX-A113splice mutation is the most prevalent in advanced thyroid cancer. EIF1AX-A113splice variants stabilize the PIC and induce ATF4, a sensor of cellular stress, which is co-opted to suppress EIF2α phosphorylation, enabling a gen- eral increase in protein synthesis. RAS stabilizes c-MYC, an effect augmented by EIF1AX-A113splice. ATF4 and c-MYC induce expression of amino acid transporters and enhance sensitivity of mTOR to amino acid supply. These mutually reinforcing events generate therapeutic vulnerabilities to MEK, BRD4, and mTOR kinase inhibitors. SIGNIFICANCE: Mutations of EIF1AX, a component of the translation PIC, co-occur with RAS in advanced thyroid cancers and promote tumorigenesis.
    [Show full text]
  • TRACE: Tennessee Research and Creative Exchange
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 8-2009 Structure-Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae James Wesley Fairman University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Biochemistry, Biophysics, and Structural Biology Commons Recommended Citation Fairman, James Wesley, "Structure-Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae. " PhD diss., University of Tennessee, 2009. https://trace.tennessee.edu/utk_graddiss/49 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by James Wesley Fairman entitled "Structure- Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Biochemistry and Cellular and Molecular Biology. Chris G. Dealwis,
    [Show full text]
  • Global Analysis of LARP1 Translation Targets Reveals Tunable and Dynamic Features of 5′ TOP Motifs
    Global analysis of LARP1 translation targets reveals tunable and dynamic features of 5′ TOP motifs Lucas Philippea,1, Antonia M. G. van den Elzena,1, Maegan J. Watsona, and Carson C. Thoreena,2 aDepartment of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06510 Edited by Alan G. Hinnebusch, National Institutes of Health, Bethesda, MD, and approved January 29, 2020 (received for review July 25, 2019) Terminal oligopyrimidine (TOP) motifs are sequences at the 5′ ends recent findings have hinted that the RNA-binding protein La- of mRNAs that link their translation to the mTOR Complex 1 related protein 1 (LARP1) may have a central role (8–10). (mTORC1) nutrient-sensing signaling pathway. They are com- LARP1 is a large protein (150 kDa) with several RNA-binding monly regarded as discrete elements that reside on ∼100 mRNAs domains. Its central region contains a La motif (LaM) domain that mostly encode translation factors. However, the full spectrum that defines the La-related protein (LARP) superfamily, along of TOP sequences and their prevalence throughout the transcrip- with an adjacent RNA recognition motif-like (RRM-L) domain. tome remain unclear, primarily because of uncertainty over the Its C terminus encodes a domain known as the DM15 region. This mechanism that detects them. Here, we globally analyzed trans- domain is unique to LARP1 and its closely related homolog lation targets of La-related protein 1 (LARP1), an RNA-binding pro- LARP1B, and is therefore also known as the LARP1 domain (11). tein and mTORC1 effector that has been shown to repress TOP Several observations suggest that LARP1 directly represses TOP mRNA translation in a few specific cases.
    [Show full text]
  • Relevance of Translation Initiation in Diffuse Glioma Biology and Its
    cells Review Relevance of Translation Initiation in Diffuse Glioma Biology and its Therapeutic Potential Digregorio Marina 1, Lombard Arnaud 1,2, Lumapat Paul Noel 1, Scholtes Felix 1,2, Rogister Bernard 1,3 and Coppieters Natacha 1,* 1 Laboratory of Nervous System Disorders and Therapy, GIGA-Neurosciences Research Centre, University of Liège, 4000 Liège, Belgium; [email protected] (D.M.); [email protected] (L.A.); [email protected] (L.P.N.); [email protected] (S.F.); [email protected] (R.B.) 2 Department of Neurosurgery, CHU of Liège, 4000 Liège, Belgium 3 Department of Neurology, CHU of Liège, 4000 Liège, Belgium * Correspondence: [email protected] Received: 18 October 2019; Accepted: 26 November 2019; Published: 29 November 2019 Abstract: Cancer cells are continually exposed to environmental stressors forcing them to adapt their protein production to survive. The translational machinery can be recruited by malignant cells to synthesize proteins required to promote their survival, even in times of high physiological and pathological stress. This phenomenon has been described in several cancers including in gliomas. Abnormal regulation of translation has encouraged the development of new therapeutics targeting the protein synthesis pathway. This approach could be meaningful for glioma given the fact that the median survival following diagnosis of the highest grade of glioma remains short despite current therapy. The identification of new targets for the development of novel therapeutics is therefore needed in order to improve this devastating overall survival rate. This review discusses current literature on translation in gliomas with a focus on the initiation step covering both the cap-dependent and cap-independent modes of initiation.
    [Show full text]